Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria.
Sheikh
Javed
J
D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies / Q000276:immunology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D001491:Basophils / Q000276:immunology / Q000378:metabolism; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011755:Pyrophosphatases / Q000378:metabolism; D017455:Receptors, IgE / Q000276:immunology; D012882:Skin Tests; D014581:Urticaria / Q000188:drug therapy* / Q000276:immunology
D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001323:Autoantibodies; C427944:ENPP3 protein, human; D017455:Receptors, IgE; D000069444:Omalizumab; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases